PRLB Stock Analysis: Proto Labs | NYSE
Metal Fabrication | NYSE, USA | Market Cap: 1.789m USD | 12M Return: 85% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.2M
EPS Trend: 61.1%
Qual. Beats: 4
Rev. Trend: 83.5%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Proto Labs, Inc. (NYSE: PRLB) is a U.S.-based digital manufacturer of custom parts, operating primarily in the United States and Europe. Founded in 1999 and headquartered in Maple Plain, Minnesota, the company went public on February 24, 2012, and is classified within the Industrials sector under the GICS Industrial Machinery & Supplies & Components sub-industry, with a small-cap market capitalization of approximately $1.93 billion.
The company provides on-demand manufacturing services spanning injection molding, computer numerical control (CNC) machining, 3D printing (additive manufacturing), and sheet metal fabrication. Its customer base consists primarily of product developers, design engineers, and supply chain teams who require low-volume, custom-manufactured components. Proto Labs operates within the broader digital manufacturing segment, which uses internet-enabled quoting and ordering workflows to produce prototype and low-volume production parts without requiring traditional tooling-heavy setup.
Proto Labs service mix positions it at the intersection of several industrial subsectors, including contract manufacturing and additive manufacturing. The company competes in a fragmented market against both regional job shops and other digital manufacturing platforms, with its integrated multi-process offering (covering plastics, metals, and additive techniques) distinguishing it from single-technology providers.
- CNC and molding revenue declines on industrial slowdown
- 3D Hubs marketplace expansion boosts margins and customer reach
- European demand softness pressures revenue and operating margins
| Net Income: 25.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -2.27 > 1.0 |
| NWC/Revenue: 32.56% < 20% (prev 26.51%; Δ 6.05% < -1%) |
| CFO/TA 0.09 > 3% & CFO 73.7m > Net Income 25.8m |
| Net Debt (-133.7m) to EBITDA (69.6m): -1.92 < 3 |
| Current Ratio: 3.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.3m) vs 12m ago -0.61% < -2% |
| Gross Margin: 44.86% > 18% (prev 44.36%; Δ 0.50% > 0.5%) |
| Asset Turnover: 72.06% > 50% (prev 67.69%; Δ 4.37% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.23 (Total Current Assets 248.6m - Total Current Liabilities 70.7m) / Total Assets 778.6m |
| B: 0.32 (Retained Earnings 248.9m / Total Assets 778.6m) |
| C: 0.05 (EBIT TTM 36.4m / Avg Total Assets 758.0m) |
| D: 7.16 (Book Value of Equity 683.1m / Total Liabilities 95.4m) |
| Altman-Z'' = 10.38 = AAA |
| DSRI: 1.06 (Receivables 86.7m/74.8m, Revenue 546.3m/499.2m) |
| GMI: 0.99 (GM 44.36% / 44.86%) |
| AQI: 0.94 (AQ_t 0.41 / AQ_t-1 0.43) |
| SGI: 1.09 (Revenue 546.3m / 499.2m) |
| TATA: -0.06 (NI 25.8m - CFO 73.7m) / TA 778.6m) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of July 13, 2026, the stock is trading at USD 74.40 with a total of 130,310 shares traded. Over the past week, the price has changed by -2.62%, over one month by -5.75%, over three months by +18.43% and over the past year by +85.03%.
Current recommended Stop Loss: 69.80 (which is 6.2% or 1.6 ATR below the current price).
Proto Labs has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PRLB.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 88 | 18.3% |
P/E Trailing = 70.9245
P/E Forward = 32.2581
P/S = 3.2747
P/B = 2.5413
P/EG = 0.8585
Revenue TTM = 546.3m USD
EBIT TTM = 36.4m USD
EBITDA TTM = 69.6m USD
Long Term Debt = 1.38m USD (estimated: total debt 2.62m - short term 1.24m)
Short Term Debt = 1.24m USD (from shortTermDebt, last quarter)
Debt = 2.62m USD (from shortLongTermDebtTotal, last quarter) (leases 2.62m already included)
Net Debt = -133.7m USD (calculated: Debt 2.62m - CCE 136.3m)
Enterprise Value = 1.66b USD (1.79b + Debt 2.62m - CCE 136.3m)
Interest Coverage Ratio = unknown (Ebit TTM 36.4m / Interest Expense TTM 0.0)
EV/FCF = 26.75x (Enterprise Value 1.66b / FCF TTM 61.9m)
FCF Yield = 3.74% (FCF TTM 61.9m / Enterprise Value 1.66b)
FCF Margin = 11.33% (FCF TTM 61.9m / Revenue TTM 546.3m)
Net Margin = 4.71% (Net Income TTM 25.8m / Revenue TTM 546.3m)
Gross Margin = 44.86% ((Revenue TTM 546.3m - Cost of Revenue TTM 301.2m) / Revenue TTM)
Gross Margin QoQ = 45.64% (prev 44.23%)
Tobins Q-Ratio = 2.13 (Enterprise Value 1.66b / Total Assets 778.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.62m)
Taxrate = 29.24% (10.6m / 36.4m)
NOPAT = 25.8m (EBIT 36.4m * (1 - 29.24%))
Current Ratio = 3.51 (Total Current Assets 248.6m / Total Current Liabilities 70.7m)
Debt / Equity = 0.00 (Debt 2.62m / totalStockholderEquity, last quarter 683.1m)
Debt / EBITDA = -1.92 (Net Debt -133.7m / EBITDA 69.6m)
Debt / FCF = -2.16 (Net Debt -133.7m / FCF TTM 61.9m)
Total Stockholder Equity = 670.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.40% (Net Income 25.8m / Total Assets 778.6m)
RoE = 3.84% (Net Income TTM 25.8m / Total Stockholder Equity 670.9m)
RoCE = 5.41% (EBIT 36.4m / Capital Employed (Equity 670.9m + L.T.Debt 1.38m))
RoIC = 3.78% (NOPAT 25.8m / Invested Capital 681.8m)
WACC = 11.68% (E(1.79b)/V(1.79b) * Re(11.70%) + D(2.62m)/V(1.79b) * Rd(0.0%) * (1-Tc(0.29)))
Discount Rate = 11.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.00 | Cagr: -3.49%
[DCF] Terminal Value 61.75% ; FCFF base≈67.3m ; Y1≈59.0m ; Y5≈47.7m
[DCF] Fair Price = 26.45 (EV 495.8m - Net Debt -133.7m = Equity 629.5m / Shares 23.8m; r=11.68% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 61.09 | EPS CAGR: 6.84% | SUE: 3.98 | # QB: 4
Revenue Correlation: 83.54 | Revenue CAGR: 3.03% | SUE: 1.52 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.54 | Chg30d=+0.00% | Revisions=+62% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.51 | Chg30d=+0.00% | Revisions=+38% | Analysts=5
EPS current Year (2026-12-31): EPS=2.03 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+22.1% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=2.21 | Chg30d=+0.00% | Revisions=+57% | GrowthEPS=+9.0% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: +77% (up=18, down=1)